2ⁿᵈ Edition of the Cancer R&D World Conference 2026

Abstract

Prostate cancer is routinely graded using the Gleason scoring system, based on the microscopic appearance of prostate tissue in 12-core biopsy samples. Over the years, this scoring system has undergone significant refinement to improve diagnostic precision and clinical applicability. Despite these updates, controversies persist—particularly concerning the identification and classification of small cell components, which can significantly alter both prognosis and treatment planning.

Accurate grading remains critical in determining patient management pathways. While the current criteria for each Gleason pattern are clearly defined, we hypothesize that interobserver variability still exists among pathologists. This inconsistency raises important clinical questions: Would implementing a double-read system for prostate biopsies improve diagnostic accuracy? Is such an approach financially sustainable? And what would be the impact on turnaround time for results, especially in resource-constrained settings?

Methods:
We conducted a global literature review via PubMed and news sources to explore existing data on diagnostic consistency, cost-effectiveness, and logistical considerations related to double-reading prostate biopsies.

Results:
Difficult-to-manage prostate cancer scenarios often arise when there is diagnostic ambiguity—for example, disagreement over whether a pattern 3 versus pattern 4 is present, or how to interpret cribriform architecture. Disparities in diagnosing rare variants, such as small cell carcinoma or intraductal carcinoma, further underscore the complexity of histopathological evaluation. Such cases illustrate the indispensable role of pathologists not only in grading but also in shaping multidisciplinary treatment decisions. Unfortunately, there is limited literature on the feasibility or practicality of a double-read system. Artificial intelligence may offer support in improving diagnostic accuracy and precision.

Conclusions: The Gleason grading system is critical in diagnosing and managing prostate cancer. Accurate grading by pathologists is essential since it affects treatment decisions and patient outcomes. Continuous advancements in grading methods and diagnostic technology are enhancing prostate cancer management, leading to improved patient results.